Pharmaceutical

PRO-1107 by ProfoundBio Suzhou for Endometrial Cancer: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Endometrial Cancer.

Apr 21, 2024 - 00:00
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Endometrial Cancer.
Read the original article

Tags:

Previous Article

PRO-1107 by ProfoundBio Suzhou for Non-Small Cell Lung Cancer: Likelihood of App...

Next Article

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ironwood Pharmaceuticals files patent for delayed relea...

Mar 24, 2024

STAT+: A new AI tool aims to help surgeons quickly analyze brain tumor mutations during surgery

STAT+: A new AI tool aims to help surgeons quickly anal...

Apr 7, 2023

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

AstraZeneca completes Gracell Biotechnologies acquisiti...

Feb 24, 2024